Search Immortality Topics:

Page 10«..9101112..2030..»


MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive…

Posted: March 30, 2020 at 7:42 pm

MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten

Improvement in NT-proBNP and Troponin Levels Support Future Development in Non-Obstructive HCM and Heart Failure with Preserved Ejection Fraction (HFpEF)

MyoKardia to Host Webcast Conference Call at 4:30 p.m. EDT

BRISBANE, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (MYOK) today announced results from the dose-ranging MAVERICK-HCM Phase 2 clinical trial of mavacamten for the treatment of non-obstructive hypertrophic cardiomyopathy (HCM). Data were presented during a late-breaker session at the American College of Cardiologys 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC Virtual) In the MAVERICK-HCM study, mavacamten was generally well tolerated, and statistically significant improvements in key biomarkers of cardiac injury and wall stress were observed. Further, subgroup analyses of study participants with indicators of more advanced disease demonstrated clinical responses across multiple parameters among patients on active treatment versus placebo.

Non-obstructive HCM is especially challenging to treat as there are no proven or approved pharmacological therapies. Thus, for patients who develop symptoms refractory to medications, cardiac transplantation may be the only option, saidCarolynHo, M.D., Medical Director of the Cardiovascular Genetics Center at Brigham and Womens Hospital and lead author on behalf of the MAVERICK-HCM study investigators. Although the primary objective of MAVERICK was to assess the safety and tolerability of mavacamten in non-obstructive HCM, in exploratory analyses we observed an encouraging result with reductions in serum levels of NT-proBNP, a biomarker of hemodynamic stress, and also cardiac troponin I, a biomarker of myocardial injury. We believe MAVERICK is the first study to show an improvement in important serum biomarkers in this patient population and suggests that there is potential physiological benefit from the drug. We were also intrigued by findings that patients with more severe disease expression, those with elevated serum troponin levels or evidence of diastolic dysfunction by echo, may have achieved functional benefit. These findings, combined with mavacamtens tolerability profile, are encouraging, and they provide direction for further evaluation of mavacamten for patients with non-obstructive HCM.

MAVERICK has succeeded in providing us with the important data we needed to proceed in our planned clinical trials in non-obstructive HCM, as well as a targeted subset of patients with heart failure with preserved ejection fraction, or HFpEF. We gained unique insights into dosing strategies using markers linked to clinical benefit, as well as how to identify patients who may be most likely to benefit from mavacamten, said Jay Edelberg, M.D. Ph.D., MyoKardias Senior Vice President of Development. The MAVERICK results also further our confidence in mavacamtens development in obstructive HCM, as we approach our Phase 3 EXPLORER-HCM readout, which is expected in the second quarter.

MAVERICK-HCM ResultsSafety and Tolerability ObservationsMavacamten was generally well tolerated, consistent with prior clinical studies.

Effect on Exploratory Endpoints of Efficacy: Biomarkers of Cardiac Wall Stress and Injury Among several pre-specified endpoints analyzed, treatment with mavacamten resulted in significant changes in circulating biomarkers associated with heightened risks of cardiac complications.

For the intent-to-treat population, no difference was observed between active and placebo groups in the other exploratory endpoints.

The effect of mavacamten on NT-proBNP and cardiac troponin levels in non-obstructive HCM patients is a first-of-its-kind finding for a product candidate in this patient population, said Michael R.Zile, M.D.,Director of Cardiology, Ralph H. Johnson VA Medical Center. NT-proBNP is a measure of cardiac wall stress, and elevated troponins signal heart muscle injury, both of which have been established in the literature as prognosticators of dire complications in both HCM and HFpEF patients, including the need for hospitalizations, surgical intervention and death. The reductions in biomarkers associated with poor outcomes are encouraging, and I look forward to seeing the potential for mavacamten to impact outcomes in HCM, as well as certain targeted HFpEF populations, over time.

Story continues

Patient Subgroups with Advanced Diastolic Disease MyoKardia also shared its analyses of the effect of mavacamten treatment on two subgroups of patients with advanced disease: one comprising 19 of the 59 enrolled patients (32%) with elevated cardiac troponin levels of >0.03ng/mL and another including 25 patients (42%) who had elevated filling pressures, defined by E/e >14(4). HCM patients with higher cardiac troponin levels are known to be at greater risk for serious complications, and elevated filling pressures are indicative of impaired diastolic compliance, or the ability of the left ventricle to relax and fill with oxygenated blood.

A trend toward potential benefit was observed across numerous clinical measurements in patients with elevated cardiac troponin I levels and those with higher diastolic filling pressures versus placebo:

Composite Functional Endpoint Analysis A composite functional endpoint(4) analysis was utilized to compare responses among the intent-to-treat population and the subgroups of patients with more advanced disease to those within the placebo population.

Based on our observations that multiple markers responded to mavacamten, we believe we may be able to utilize markers of likely clinical benefit to guide dosing in the non-obstructive HCM patient population moving forward, similar to the way we are utilizing LVOT gradient to guide dosing in obstructive HCM, said Jay Edelberg, M.D., Senior Vice President, Development at MyoKardia. Additionally, we observed in MAVERICK that patients who were most impaired showed the most meaningful trends toward benefit with mavacamten treatment within the 16-week treatment period. We look forward to leveraging these learnings, as well as knowledge gained from the longer exposures to treatment provided by our long-term extension study, as we look to advance mavacamten for the treatment of non-obstructive HCM patients and adjacent HFpEF populations.

Data from the MAVERICK-HCM Phase 2 clinical trial were presented by Carolyn Ho, M.D., Medical Director of the Cardiovascular Genetics Center at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School, during the American College of Cardiologys Annual Scientific Session together with World Congress of Cardiology virtual meeting this morning during the Featured Clinical Research III Session in a presentation titled Mavacamten Improves Biomarkers Of Myocardial Wall Stress And Injury In Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM): Results From The Phase 2 MAVERICK-HCM Study (#412-16).

About the Phase 2 MAVERICK-HCMClinical TrialThe Phase 2 MAVERICK-HCM trial assessed the safety and tolerability of a range of exposures over 16 weeks of treatment in patients with symptomatic, non-obstructive HCM. All study participants were required to be diagnosed with non-obstructive HCM, with left ventricular wall thickness either 15mm or 13mm with a family history of HCM,New York Heart Association(NYHA) classifications of Class II or III, and NT-proBNP levels of greater than 300 pg/mL at rest.Baseline characteristics, such as age, weight, gender, pathogenic mutation status, background beta blocker use, NYHA classification and exercise capacity were evenly distributed between active and placebo arms.

A total of 59 participants were enrolled in the study and randomized into one of three groups to receive once-daily doses of mavacamten or placebo.The active mavacamten treatment arms were designed to assess a range of drug concentrations around target levels of 200 ng/mL and 500 ng/mL. All participants in the active treatment arms began the study receiving 5mg doses of mavacamten. At Week 4, pharmacokinetic (PK) assessments were conducted and doses were adjusted in a blinded fashion per the protocol based on the participants assigned cohort. Following the 16-week treatment period, participants were monitored for an additional 8 weeks and became eligible to participate in MyoKardias MAVA Long-Term Extension (LTE) study.

Conference Call and WebcastMyoKardia management will also host a virtual event for investors and analyst today to review the data from MAVERICK-HCM and discuss future development plans for mavacamten in targeted groups of patients with diastolic disease. This live webcast event will begin at 4:30 p.m. EDT / 1:30 p.m. PDT and include remarks by Dr. Anjali Owens, Medical Director, Center for Inherited Cardiac Disease at the University of Pennsylvania, and Dr. Michael Zile, Professor of Medicine at the Medical University of South Carolina.

To access the call, please dial (844) 494-0193 (U.S.) or (508) 637-5584 (international), and reference the conference ID 2982709. A live webcast of the event will be available on the Investors section of MyoKardias website at http://investors.myokardia.com. A replay of the webcast, and accompanying slides, will be available on theMyoKardiawebsite for 90 days following the call.

About Non-obstructive HCM and Heart Failure with preserved Ejection FractionHypertrophic cardiomyopathy is the most common genetic form of heart disease, affecting an estimated one in every 500 people worldwide.There are two main forms of HCM, obstructive HCM and non-obstructive HCM, which often share the same underlying genetic defects in the sarcomere that result in hypercontractility.In non-obstructive HCM, the heart contracts excessively and the left ventricle becomes abnormally thick, restricting the ability of the heart to relax and fill or pump to meet the bodys needs, but no physical obstruction is present in the outflow tract of the left ventricle. Non-obstructive HCM affects an estimated one-third of all HCM patients and presents unique treatment challenges.Patients may progress to a more advanced state of disease than those with obstructive disease before being diagnosed, and there are no approved pharmacological treatment options available.As non-obstructive HCM progresses, symptoms begin to resemble those of a congestive heart failure patient and heart transplantation may become the only viable treatment option.

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical syndrome, which in many patients is characterized by impairment of the left ventricles ability to relax and fill during diastole, resulting in insufficient blood flow to meet the bodys needs.HFpEF is estimated to affect approximately three million people in the U.S. and is associated with significant morbidity and mortality. There are currently no approved therapies for HFpEF.

About Mavacamten (MYK-461)Mavacamten is a novel, oral, allosteric inhibitor of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). Mavacamten is intended to reduce cardiac muscle contractility by inhibiting the excessive myosin-actin cross-bridge formation that underlies the excessive contractility, left ventricular hypertrophy and reduced compliance characteristic of HCM.MyoKardiais currently evaluating mavacamten in multiple clinical trials for the treatment of obstructive and non-obstructive HCM. The pivotal Phase 3 clinical trial, known as EXPLORER-HCM, is being conducted in patients with symptomatic, obstructive HCM andMyoKardiaanticipates data from this program in the second quarter of 2020. Two long-term follow-up studies are also ongoing, the PIONEER open-label extension study of obstructive HCM patients from MyoKardias Phase 2 PIONEER trial and the MAVA-LTE, an extension study for patients who have completed either EXPLORER-HCM or MAVERICK-HCM, the companys Phase 2 clinical trial of symptomatic non-obstructive HCM patients. InApril 2016, the U.S.FDAgranted Orphan Drug Designation for mavacamten for the treatment of symptomatic obstructive HCM.

About MyoKardiaMyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardias initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.

MyoKardias mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Forward-Looking StatementsStatements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten, our plans to advance the clinical development of mavacamten in non-obstructive HCM patients and a targeted population of HFpEF patients, the anticipated data readout from our Phase 3 EXPLORER trial of mavacamten, our plans to consult with the FDA on potential pathways to registration and to provide a regulatory update, the initiation, progress and availability of data from our ongoing and planned clinical trials, and the timing of these events, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts Michelle Corral Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir@myokardia.com

Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com

Julie Normant (media)W2O628-213-3754jnormart@w2ogroup.com

See original here:
MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive...

Recommendation and review posted by G. Smith

Solving the Challenge of a Lifetime – University of Denver

Posted: March 30, 2020 at 7:42 pm

When Amber Freed (MACC 04) graduated from Daniels College of Business at DU, she knew her education had prepared her for an exciting career in finance. What she didnt expect was how well it would prepare her for her lifes work: fighting for her sons life.

In 2018, Amber and her husband, Mark, had noticed that their son, Maxwell, was not achieving the same milestones as his twin sister, Riley. He didnt reach for toys or use his hands to grasp. After extensive genetic testing, the Denver couple received news of their 16-month-old sons diagnosis: SLC6A1. So rare that it doesnt have a name and is referred to by the affected gene, the disease causes developmental delay and the onset of debilitating epilepsy by age 3 or 4, as Amber describes. Time was of the essence Maxwell needed treatment before that stage to prevent irreversible neurological damage.

The problem was that no treatment for SLC6A1 yet existed. Amber decided to help create it.

Amber was working as an equity analyst at Janus Henderson Investors at the time of her sons diagnosis, and she quit her job the day she heard the news. She would dedicate her energy full time to finding the solution gene replacement therapy for Maxwell and other children with SLC6A1. Since that time, she says she has devoted 80 hours per week to networking with scientists, physicians, and pharmaceutical companies, in addition to caring for her twin children and providing multiple therapies for Maxwell.

Solving big social issues, Amber says, is a skill she learned during her time at the University of Denver. A member of the Pioneer Leadership Program, she was drawn to DU because of its high values and mission, as well as the way the University pulls students together. She came from a life of poverty in Pueblo about two hours south of Denver with little parental support. She knew education was the key to making a better life for herself.

At DU, Amber found a community of people who would take her under their wing and help her manage lifes challenges and solve problems along her educational journey. She emerged from DU with an understanding that the way to change the world is by solving a huge societal issue. She says finding a cure for Maxwell and others affected by the same genetic disease is the most consequential challenge of her life.

Throughout my education at DU, in addition to my major, DU supplied me with the tools to teach me how to think and how to solve a problem by bringing key stakeholders together, while using the highest moral integrity to do so, Amber says. Even though accounting was my major, with Maxwells diagnosis I was forced to become an expert in microbiology overnight. The holistic DU experience is what separates DU from everyone else. This isnt a path that I would have expected, but DU prepared me to do it.

Working with Dr. Steven Gray at the University of Texas Southwestern Medical Center in Dallas, Amber says she is about to set the record for fastest time from newly discovered disease to curative treatment. She is in the process of raising $4 million to fund the research and clinical trials for SLC6A1.

This treatment is Maxwells only chance at life, and in her advocacy, Amber feels she is speaking for all the children with SLC6A1 who dont have a voice. The treatment itself, she says, is once and done: a two-hour process that uses a harmless virus to replace the faulty DNA in the childs body. It sounds like science fiction, Amber says, but its possible today.

The impact for the disease itself will have an effect far beyond her family, Amber says. She and Dr. Gray envision SLC6A1 being a part of a newborn screening panel: babies will be screened and treated before they leave the hospital. Since its a single treatment that changes the DNA and solves the issue, those babies will never get sick from the disease. Additionally, the treatment approaches of other diseases affected by the same gene would benefit greatly from Dr. Grays work.

My dream is for there to never be another child with SLC6A1, Amber says. I dont want any other family to go through what we are going through.

To the DU community, Amber has one message: Thank you.

This is every parents worst nightmare, and the only way to solve it is through collective effort of knowledge, resources, and kindness. Ive been blown away by DU. Im so proud to be an alum, she says.

In 2012, Amber was highlighted in the book Shortcut to Prosperity as an example of grit. She says a great deal of her grit came from her DU experience. Because of her DU education, Amber says, something nearly miraculous is coming from a person who really didnt have a chance at life.

Her DU network continues to join her in the journey. Ambers first call for volunteers was on a Pioneer Leadership Program Facebook group. Undergraduate student Brandon Prentice was the first to step forward, offering to use his biology background to help in any way he could. Now he has a role within Ambers organization and is the primary author on a research paper a tremendous accomplishment for an undergraduate student. Brandon is about to start medical school at Oakland University William Beaumont, and he has a new vision for his career: curing rare diseases.

As the director of research for SLC6A1 Connect, I partnered with Amber as she began developing a cure for SLC6A1-related disorders, says Prentice. Though Amber was already well positioned to undertake such a daunting task, I served as her scientific tour guide as she entered the complex world of medicine. I provided briefings on research articles, defined laboratory tools like recombinant DNA, and acted as a sounding board as she chose what to do next. I am beyond grateful that I had the opportunity to further develop these skills and am even more grateful for the time observing Ambers strengths. She has advocated for those who are suffering, she has displayed compassion, she has overcome setbacks, and she has provided direction for the medical community. Amber is impressive, and I hope to emulate that same vigor as a future physician.

Ambers fellow accounting major Nat Borchers of Colorado Rapids and Portland Timbers soccer fame reached out to his network and obtained signed sports memorabilia for Ambers silent auction. DUs head basketball coach, Rodney Billups, is participating in Ambers upcoming fundraising golf tournament. Those are just a few of her DU connections helping her to solve the problem of a lifetime.

Ambers mission her tireless work to solve SLC6A1 for Maxwell and other children is one of hope and progress. Her DU education and her DU network are joining her every step of the way.

More here:
Solving the Challenge of a Lifetime - University of Denver

Recommendation and review posted by G. Smith

The Conversation: What you need to know about pregnancy in the time of COVID-19 – Generocity

Posted: March 30, 2020 at 7:42 pm

This article is republished from The Conversation under a Creative Commons license. It follows that sites stylistic conventions. Read the original article here.

That question, sent to me by a colleague who is both a registered nurse and an expectant mother, stopped me in my tracks.As an OB-GYN physician, I naturally focus on the science of health care. Her email reminded me of the uncertainty expectant mothers now face as health risks and the health care system around them change amid this coronavirus pandemic.

While knowledge about the new coronavirus disease, COVID-19, is rapidly evolving and there are still many unknowns,medical groupsand studies are starting to provideadviceand answers to questions many expecting families are asking.

So far, the data on COVID-19 does not suggest pregnant women are at higher risk of getting the virus, according to theAmerican College of Obstetricians and Gynecologists. However, as we have seen fromthe fluthey are at greater risk of harm if they get respiratory infections. Pregnancy causes a variety of changes in the body and results in a slight immunocompromised state which can lead to infections causing more injury and damage.

Studies have not yet been done to show if having COVID-19 during pregnancy increases the chance of miscarriage, but there is some evidence from other illnesses. During the SARS coronavirus epidemic in 2002-2003, women with the virus were found to have a slightly higher risk of miscarriage, but only those who wereseverely ill.

Having respiratory viral infections during pregnancy, such as the flu, has been associated with problems likelow birth weight and preterm birth. Additionally, having ahigh feverearly in pregnancy may increase the risk of certain birth defects, although the overall occurrence of those defects is still low.

This data is evolving fast. Two papers published March 26 describe findingcoronavirus antibodiesin three newborns of mothers with COVID-19. That could suggest they had been exposed to the virus in the womb, though the virus itself was not detected in their umbilical cord blood and researchers haveraised questionsabout the type of test used. Researchers in anearlier studyfound no evidence of COVID-19 in the amniotic fluid or cord blood of six other infants born to infected women. While the research papers include only a small number of cases, a lack of vertical transmission from the mother to child in utero would be consistent with what is seen with other common respiratory viral illnesses in pregnancy, such as influenza.

There have beena few reportsof newborns as young as a few days old with infection. But in those cases, it is believed that the mother or a family member transmitted the infection to the infant through close contact after delivery. The virus can be transmitted through a cough or sneeze, which could spread virus-laden droplets on a newborn.

Prenatal care may look different for a while to control the spread of COVID-19 among patients, caregivers and medical staff.

Typically, a pregnant woman has about 14 prenatal visits. That may bereduced by approximately half, with telemedicine playing a larger role. Telemedicine is already endorsed by the American College of Obstetricians and Gynecologists forpatients in rural settings. Now, the pandemic is making virtual care solutions an indispensable tool. Pregnant women are able to do some at-home monitoring, such as for high blood pressure, diabetes and contractions, and telemedicine can even be used by pregnancy consultants, such as endocrinologists and genetic counselors.

The frequency of sonogram appointments may also change. The Society of Maternal Fetal Medicine says it issafe to reduce routine ultrasoundsat this time without jeopardizing the health and safety of the pregnancy. Of course, some patients with specific conditions like twins or babies with suspected birth defects may require more traditional follow up.

Hospitals are doing what they can to minimize person-to-person transmission, and that may mean delivery looks different, too. Some hospitals are screening all medical staff, including withtemperature checks, at the start of shifts.

Visitors are also being restricted. Recently, a hospital in New York enforced ano visitor policy, including partners, for patients about to give birth, citing coronavirus risk. This is definitely not what laboring women envision for their delivery, but in times of widespread communicable disease, it is reality.

No. Having COVID-19 is not a reason for a cesarean. Theresno evidencethat either method, vaginal birth or cesarean, is safer when it comes to COVID-19. Although data is still limited, other coronavirus infections have not been known to pass to the child from vaginal birth.

Both the American College of Obstetricians and Gynecologists and the Society of Maternal Fetal Medicine believe, in most cases, the timing of delivery should not be dictated by the mothers COVID-19 diagnosis. Women infected early in pregnancy who recover should see no change to their delivery schedule. For women infected later in pregnancy, it is reasonable to attempt to postpone the delivery, as long as no other medical reason arises, until the mother receives a negative test result.

Expect a faster discharge from the hospital. To limit the risk of inadvertent exposure and infection, the ACOG saysdischarge may be consideredafter 12 to 24 hours, rather than the usual 24 to 48 hours for women with uncomplicated vaginal births, and after two days for women with cesarean births, depending on their health status.

For mothers with confirmed COVID-19, the Centers for Disease Control and Prevention advises thatinfants be isolated from them, which understandably is not ideal. That could mean drawing a curtain between the mother and newborn and keeping them at least six feet apart. The CDC suggests continuing that separation until 72 hours after the mothers fever is gone. If no other healthy adult is present in the room to care for the newborn, a mother who has confirmed or suspected COVID-19 should put on a facemask and practice hand hygiene before each feeding or other close contact with her newborn.

If a woman chooses to have her baby in a hospital or birthing center, she will have a dedicated team of health care providers trained to protect her and her baby from COVID-19 and handle any unforeseen complications. There is some concern regarding person-to-person exposure with COVID-19 in a home birth setting due to fewer restrictions on visitors. Although the ACOG has not made a statement specifically on this risk, theUnited Kingdoms Royal College of Obstetricians and Gynaecologistshas a statement advising against home birth for women who have been exposed to COVID-19.

Inlimited casesreported to date, no evidence of virus has been found in thebreast milk of women infectedwith COVID-19; however, precautions are still recommended. Breastfeeding is encouraged and is a potentially important source of antibody protection for the infant. The CDC recommends that during temporary separation, women who intend to breastfeed should be encouraged to pump their breast milk to establish and maintain milk supply. The mother should wash her hands before touching any pump or bottle parts. If possible, it is alsorecommendedto have someone who is healthy feed the infant.

Having a child is a momentous occasion that should be celebrated, including during a pandemic. Do your part to keep yourself healthy. Wash your hands, maintain social distance and keep in close contact with your health care providers throughout the pregnancy. It may not be what you envisioned, but you will have quite a story to tell your children.

###

[You need to understand the coronavirus pandemic, and we can help. Read our newsletter.]

Read the original:
The Conversation: What you need to know about pregnancy in the time of COVID-19 - Generocity

Recommendation and review posted by G. Smith

The research team’s hypothesis: Genes may determine how badly affected the corona to – Wire News Fax

Posted: March 30, 2020 at 7:42 pm

if you can Find peoples genes explanation as to how serious the corona virus infection from different people coming from? This is not yet known. Scientists, however, believe that genetic factors may affect disease individual progression.

in Statistical genetics and epidemiology researcher Andrea Ganna the Finnish institute for molecular medicine FIMMist and his colleagues started the international cooperation process (switch to another service), where they are looking for corona virus patients DNA samples, connections to the predisposition to and severity of disease.

the vast Majority of people symptoms of the disease are very mild, and only some virus received with severe case of pneumonia.

our Hypothesis is that individuals genetics can explain the variation of the corona in the symptoms. We want to find the patients DNA mutations that could explain it, how serious the disease becomes, Ganna said.

the Purpose is to compare severe symptoms, but received no risk categories of patients DNA in patients with only minor or no symptoms.

Variations in ACE2 receptor, which is a corona virus used by invading cells within, can make the virus to travel from cell to either the hard or easily, said the Science magazine (you move to another service) immunologist Philip Murphy , whose laboratory discovered a fairly common mutation in another human cell membrane protein, which makes other people very resistant to HIVille.

possible to find a remedy for the corona virus treatment

the Project benefits would show up as in drug development than treatment of patients in the organisation.

we Know that certain drugs target specific genes. If these genetic mutations are also associated with COVIDIEN-19-severity of disease, it is possible that this drug could quite easily and quickly also use a corona virus infection.

If again manifested, that some people have a low genetic risk of getting severe symptoms, this information can be Gannan, according to the use of the treatment prioritization.

Data collected from around the world

Ganna and his colleagues has asked biobanks, hospitals and research institutions around the world to submit data to the corona virus patients DNA samples. Interested institutions can register according to the initiatives website (go to another service).

Gannan group does not handle DNA samples, but samples senders pretreatment genetic information, where you can find information about data science methods.

fimm is the director of Mark Daly is, in turn, promised that the FIMM makes DNA genotyping and analysis, if any institution does not have the resources to do it yourself. Gannan group edit the DNA data into a single format and publish them to the scientific community available.

in March, started the initiative has already collected a dozen partners, mostly in Europe and the united states. Also included is the Finngas (you move to another service), which has dna samples and health data for five percent of the Finnish population.

the Significant cooperation of the Italian Siena with the university. In siena, scientists collect samples of the 11 hospital in the North of Italy. The first samples came fimm was months.

Research is northern Italian to Gannan, but also personal meaning.

Im originally from Lombardia, where the corona virus infection have been highest in Italy. I know people who are seriously ill, so yes this is also a personal component, he said.

Also institute for Health and welfare THL to start their own national investigation of serious corona of symptoms predisposing factors. Research participate in an independent study also this international cooperation project.

the topic of the news also of the American Association for the Advancement of Science, published by science magazine Science Magazine (you move to another service).

see also :

Finnish drug hope to prevent the corona of deaths significantly First, however, it should also pass the United states medical authorities of the tests

the Problem overdrive the immune system this corona virus strikes the diseased

the Latest information about the corona virus in Finland and from the world

subscribe to news about the corona virus

Get the Yle main corona virus news to your email once a day.

Proceed to order

Read the original:
The research team's hypothesis: Genes may determine how badly affected the corona to - Wire News Fax

Recommendation and review posted by G. Smith

Coronavirus, Intelligent Design, and Evolution – Discovery Institute

Posted: March 30, 2020 at 7:42 pm

Many people have been wondering about the relevance of intelligent design (ID) or evolution to the new coronavirus reported in Wuhan, China, in December 2019. What follows is my view as a molecular biologist.

The new virus goes by several names. It was initially called 2019-nCoV by the World Health Organization (with n standing for new). Since its DNA sequence is similar to that of the coronavirus that caused Severe Acute Respiratory Syndrome (SARS) in 2003, the International Committee on Taxonomy of Viruses renamed it SARS-CoV-2 in March 2020. The disease caused by the virus has been called COVID-19 (with d standing for disease).

There are other coronaviruses (including MERS-CoV, the virus that caused the 2012 epidemic of Middle East Respiratory Syndrome). To avoid confusion, I will refer to the latest coronavirus by its technical name, SARS-CoV-2.

Some people have maintained that SARS-CoV-2 is a product of human design. According to a February New York Post article, it may have escaped from a microbiology laboratory at the Wuhan Institute of Virology. But I have seen no scientific evidence to support this claim.

On March 17, 2020, an analysis of DNA from several different coronaviruses was published in Nature Medicine. The authors concluded, Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus.

Jonathan Bartlett, who has studied the logic of design inferences in depth, subsequently argued that the scientists had ruled out only one design hypothesis, so design was still theoretically possible. But Bartlett did not maintain that SARS-CoV-2 is a product of human design.

Could SARS-CoV-2 have evolved from another coronavirus by mutation and natural selection? I dont see why not, though there is only indirect evidence (from DNA sequences) to support the idea. If it had happened, however, it would not provide support for Darwinian evolution.

First, viruses are not living organisms: They are just pieces of DNA or RNA enclosed in a protein coat. They do not carry out metabolism (the chemical processes that are essential for life), and they do not reproduce themselves (only living cells or skilled genetic engineers can make copies of them). Second, even if viruses were considered living things, the evolution of SARS-CoV-2 from another coronavirus would be akin to microevolution minor changes within existing biological species. (Species are not even defined the same way in viruses as they are in living organisms.)

But Darwin did not write a book titled How Existing Species Change Over Time. He wrote a book titled The Origin of Species. In other words, Darwin attempted to explain macroevolution the origin of new species, organs, and body plans.

What, then, is the relevance of ID or evolution to SARS-CoV-2? As we have seen, their relevance to the origin of the coronavirus is unclear. But what about their relevance to combating the disease, COVID-19? According to Darwinist Theodosius Dobzhansky (who distinguished between microevolution and macroevolution in the 1930s), nothing in biology makes sense except in the light of evolution. In 2003, Texas Tech University professor Michael Dini wrote:

The central, unifying principle of biology is the theory of evolution. How can someone who does not accept the most important theory in biology expect to properly practice in a field [medicine] that is so heavily based on biology?

Yet the measures being taken against the SARS-CoV-2 pandemic owe nothing to evolutionary theory. The use of quarantine to block the spread of disease began in the fourteenth century. In the 1790s, Edward Jenner vaccinated people to protect them from smallpox. In 1847, Hungarian obstetrician Ignc Semmelweis demonstrated that proper hand washing lowers mortality from infectious disease. The administration of oxygen to patients with labored breathing was first reported in the years just following the publication of The Origin of Species, but the practice was based on physiological and clinical considerations, not evolution. And if any treatments are found to cure COVID-19 or lessen its effects, they will come from the intelligently designed efforts of virologists, biochemists, and clinicians not evolutionary biologists.

Photo credit: Airman 1st Class Alexis Christian, via Peterson Air Force Base.

Read more here:
Coronavirus, Intelligent Design, and Evolution - Discovery Institute

Recommendation and review posted by G. Smith

Non-Profit Offers Free Stem Cell Therapy to Veterans – Pain News Network

Posted: March 30, 2020 at 7:41 pm

By A. Rahman Ford, PNN Columnist

No group is more worthy of the revolutionary benefits of stem cell therapy than Americas military veterans. While the U.S. Department of Veterans Affairs (VA) thinks the field is in its infancy and much more research is needed before stem cells are offered as treatment, brave practitioners are stepping forward to help veterans NOW.

Dr. Joseph Kanan and his staff at the Tullahoma Chiropractic Center are providing free stem cell therapy for veterans who suffer from chronic pain. Kanan in partnership with Veterans in Pain recently performed his first pro bono procedure on a veteran named Ryan, who has severe hip pain. Stem cell injections into Ryans hip, which are not covered by insurance, normally would have cost $6,500. Ryan got them for free.

I think veterans do a lot for our country and there are very few doctors that are performing medical procedures like this, Kanan told The Tullahoma News. We were very glad to be able to do this for him.

Kanan says his Tennessee clinic performs stem cell therapy for veterans twice a month and has had good results so far. One patient was able to avoid a knee replacement and reported consistent improvement one year after the procedure. Patients can expect to experience 10 percent improvement every month for 10 months.

Veterans in Pain is a non-profit that connects military veterans with civilian physicians who provide free regenerative medicine treatments for chronic pain. VIP has provided $250,000 worth of services since 2019.

VIP founder and president Micaela Bensko is herself a stem cell therapy recipient. She spent years in a wheelchair after an accident in her driveway left her with severe spine damage that led to arachnoiditis, a chronic inflammation of spinal nerves. A friend suggested stem cell therapy, which inspired Bensko to establish VIP as a resource for veterans.

Veterans in Pain connects each veteran with a volunteer physician in their area. If one cannot be located, the cost of transportation and accommodations are covered for treatments, as they were for Ryan. Veterans associated with VIP visit schools, organizations and corporations sharing their story of recovery. Most of VIPs funding is provided by small individual donations, grants and grassroots fundraising.

According to the National Institutes of Health, nearly two-thirds of veterans report having chronic pain, with about 9% having severe pain. Chronic pain among veterans is closely associated with mental health conditions such as depression, anxiety, poor sleep and substance abuse disorders. Many veterans suffer from more than one condition.

Because of red tape and a shortage of pain management specialists at the VA, many veterans suffering from chronic pain are left devoid of proper diagnosis and treatment, causing many to self-medicate or search for answers on their own.Chronic pain can lead to substance abuse, a common and growing trend among veterans. A 2017 study found that 30% of military suicides were preceded by alcohol or drug abuse.

The dire plight of military veterans suffering from chronic pain is yet another compelling reason for the FDA to loosen its regulation of stem cell therapy. Our heroes are counting on it.

A. Rahman Ford, PhD, is a lawyer and research professional. He is a graduate of Rutgers University and the Howard University School of Law, where he served as Editor-in-Chief of the Howard Law Journal. Rahman lives with chronic inflammation in his digestive tract and is unable to eat solid food. He has received stem cell treatmentin China.

View original post here:
Non-Profit Offers Free Stem Cell Therapy to Veterans - Pain News Network

Recommendation and review posted by G. Smith


Page 10«..9101112..2030..»